血液透析患者的XI因子抑制:更安全的抗凝药?
Eleni Stamellou1, Heidi Noels2, Jürgen Floege3
1Department of Nephrology, School of Medicine, University of Ioannina, Ioannina, Greece; Division of Nephrology and Rheumatology, Rheinisch Westfälische Technische Hochschule (RWTH) University of Aachen, Aachen, Germany.
Kidney international
|June 21, 2024
概括
费索梅森的XI因子抑制对慢性血液透析患者来说是有前途的. 这种方法可以减少透析回路和动脉静脉囊中的凝血,降低出血风险.
科学领域:
- 心血管医学 心血管医学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性血液透析患者面临高心血管风险,包括血栓栓塞和出血.
- 因子XI在凝血中起作用,使其抑制成为抗凝血治疗的潜在治疗点,减少出血并发症.
研究的目的:
- 评估新型XI因子抑制剂费索梅森在慢性血液透析患者的安全性和有效性.
- 评估费索梅森对透析接入回路和动脉静脉的凝血率的影响.
主要方法:
- 在慢性血液透析患者中进行了2期临床研究.
- 给了Fesomersen,一种针对XI因子的反感性寡核酸.
- 监测了动脉静脉和透析回路的安全性和凝血率.
主要成果:
- 费索默森在研究的人群中显示出有利的安全性.
- 初步数据表明,动脉静脉和透析电路内的凝血率有所降低.
结论:
- 通过费索梅森抑制XI因子似乎是慢性血液透析的安全抗凝剂策略.
- 费索默森可以提供抗凝固的双重好处,减少出血和改善透析通道通透性.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
01:16Clot Retraction and Fibrinolysis
5.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.4K
01:11Renal Failure: Dose Adjustments
80
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
80
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517
01:25Antihypertensive Drugs: Direct Renin Inhibitors
567
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
567
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.1K